Samsara BioCapital, LLC
13F Reported Value
ⓘ$1.2B
Holdings
24
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Samsara BioCapital, LLC disclosed 24 positions worth $1.2B in its Form 13F-HR for Q2 2026, led by $SRRK (Scholar Rock Holding Corp) at 31.2% of the equity portfolio, followed by $ALMS and $MLYS. During the quarter the fund opened 4 new positions and exited 2 — including a new stake in $ALMR and a full exit from $ACLX. The portfolio is most concentrated in Healthcare (94.5% of disclosed assets). All figures are sourced directly from Samsara BioCapital, LLC’s Form 13F-HR filing with the SEC under CIK 1744967.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- —
Quality
$379.4M6,897,652 sh - 7.1#2,949
Quality
$178.6M6,345,219 sh - —
Quality
$158.4M5,871,018 sh - 59.2
Quality
$105.5M3,149,128 sh - —
Quality
$67.2M2,480,310 sh - 27.4
Quality
$54.0M1,717,127 sh - —
Quality
$52.4M12,881,175 sh - —
Quality
$47.0M2,109,953 sh - 15.3
Quality
$35.3M1,062,872 sh - —
Quality
$23.9M6,314,805 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Scholar Rock Holding Corp$SRRK | — | $379.4M | 6,897,652 |
 ALUMIS INC.$ALMS | 7.1#2,949 | $178.6M | 6,345,219 |
 Mineralys Therapeutics, Inc.$MLYS | — | $158.4M | 5,871,018 |
 Septerna, Inc.$SEPN | 59.2 | $105.5M | 3,149,128 |
 Alamar Biosciences, Inc.$ALMR | — | $67.2M | 2,480,310 |
 Neurogene Inc.$NGNE | 27.4 | $54.0M | 1,717,127 |
 Kalaris Therapeutics, Inc.$KLRS | — | $52.4M | 12,881,175 |
 SpyGlass Pharma, Inc.$SGP | — | $47.0M | 2,109,953 |
 SUTRO BIOPHARMA, INC.$STRO | 15.3 | $35.3M | 1,062,872 |
 Inventiva S.A.$IVA | — | $23.9M | 6,314,805 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Samsara BioCapital, LLC's 24 positions.
Showing top 10 of 24 holdings.
Sector Allocation
Healthcare
$1.2B
Technology
$67.2M
Full Holdings — Samsara BioCapital, LLC (Q2 2026)
All 24 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $SRRK | Scholar Rock Holding Corp | $379.4M | 31.2% | +0% | — |
| 2 | $ALMS | ALUMIS INC. | $178.6M | 14.7% | +0% | 7.1 |
| 3 | $MLYS | Mineralys Therapeutics, Inc. | $158.4M | 13.0% | +0% | — |
| 4 | $SEPN | Septerna, Inc. | $105.5M | 8.7% | +0% | 59.2 |
| 5 | $ALMR | Alamar Biosciences, Inc. | $67.2M | 5.5% | NEW | — |
| 6 | $NGNE | Neurogene Inc. | $54.0M | 4.4% | +0% | 27.4 |
| 7 | $KLRS | Kalaris Therapeutics, Inc. | $52.4M | 4.3% | -1% | — |
| 8 | $SGP | SpyGlass Pharma, Inc. | $47.0M | 3.9% | +0% | — |
| 9 | $STRO | SUTRO BIOPHARMA, INC. | $35.3M | 2.9% | +0% | 15.3 |
| 10 | $IVA | Inventiva S.A. | $23.9M | 2.0% | +22% | — |
| 11 |  $JBIO | Jade Biosciences, Inc. | $16.4M | 1.3% | -24% | — |
| 12 |  $PBLS | Parabilis Medicines, Inc. | $15.2M | 1.3% | NEW | — |
| 13 |  $VTVT | vTv Therapeutics Inc. | $11.2M | 0.9% | +0% | — |
| 14 |  $AQST | Aquestive Therapeutics, Inc. | $10.4M | 0.8% | +0% | 14.5 |
| 15 |  $NKTX | Nkarta, Inc. | $9.9M | 0.8% | +0% | — |
| 16 |  $ARTV | Artiva Biotherapeutics, Inc. | $9.3M | 0.8% | NEW | 9.7 |
| 17 |  $RANI | Rani Therapeutics Holdings, Inc. | $7.9M | 0.7% | +22% | — |
| 18 |  $AGMB | Agomab Therapeutics NV | $7.8M | 0.6% | +0% | — |
| 19 |  $ABVX | Abivax S.A. | $7.3M | 0.6% | -3% | — |
| 20 |  $XFOR | X4 Pharmaceuticals, Inc | $6.5M | 0.5% | -24% | 28 |
| 21 |  $ELOX | Eloxx Pharmaceuticals, Inc. | $5.6M | 0.5% | NEW | — |
| 22 |  $CHRS | Coherus Oncology, Inc. | $4.8M | 0.4% | +0% | 5 |
| 23 |  $UPB | Upstream Bio, Inc. | $2.4M | 0.2% | -52% | 19.7 |
| 24 |  $GOSS | Gossamer Bio, Inc. | $1.2M | 0.1% | +0% | 8.2 |
New Positions (4)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Samsara BioCapital, LLC including:
Track Samsara BioCapital, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Samsara BioCapital, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Samsara BioCapital, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For Samsara BioCapital, LLC (SEC CIK: 1744967), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Samsara BioCapital, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.